Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
Search results for: hospital
Calcium Pyrophosphate Deposition Disease Diagnosis & Treatment Gaps Remain
CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.
Balancing Optimism & Skepticism in CAR T for SLE
At ACR Convergence 2025, Joan T. Merrill, MD, overviewed the current research landscape of chimeric antigen receptor (CAR) T cell therapies for systemic lupus erythematosus (SLE), raising important scientific questions about these emerging treatments.
Meeting Management Challenges in axSpA
At this ACR Convergence 2025 session, experts discussed emerging concepts with axial spondyloarthritis, including the most effective MRI specifications for diagnosis, challenges with axial juvenile spondyloarthritis & the many mimics of axSpA.
From Conceptual Seedling to Tree of Knowledge
In a panel discussion at ACR Convergence 2025, three experts provided insight into how mentorship, personal values and more helped them develop the skills and habits necessary to become a master clinician.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Gout & Cardiometabolic Co-Morbidities
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 331
- Next Page »